AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

The Scientific Advisory Group (SAG) has been called in to assist the EMA’s CHMP human medicines committee in its review of the drug, which is vying to become the first disease-modifying therapy ...

BeiGene (BGNE) announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency issued positive opinions recommending an extended authorization for ...

The Warren, N.J., biopharmaceutical company said the European Commission will now review the CHMP's negative opinion, with a decision expected in about 67 days, adding that the drug will remain ...

with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of vilobelimab continues, with discussions ongoing and a CHMP opinion anticipated ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November ...